Aviragen Therapeutics Inc Stock Nasdaq
Equities
US0906941002
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Mar. 14 | Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 14 | Transcript : Vaxart, Inc., 2023 Earnings Call, Mar 14, 2024 |
Financials (USD)
Sales 2024 * | 14.73M | Sales 2025 * | 23.1M | Capitalization | 126M |
---|---|---|---|---|---|
Net income 2024 * | -77M | Net income 2025 * | -80M | EV / Sales 2024 * | 8.52 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 5.43 x |
P/E ratio 2024 * |
-1.57
x | P/E ratio 2025 * |
-1.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.75% |
Latest transcript on Aviragen Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Sean Tucker
FOU | Founder | - | 03-12-31 |
Phillip Eric Lee
DFI | Director of Finance/CFO | 37 | 22-12-18 |
Michael Finney
CHM | Chairman | 65 | 07-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Yedid
BRD | Director/Board Member | 66 | 19-10-24 |
Elaine Heron
BRD | Director/Board Member | 76 | 22-08-24 |
Michael Finney
CHM | Chairman | 65 | 07-06-30 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.71B | |
+1.69% | 22.02B | |
-17.37% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.85% | 15.52B | |
+3.21% | 13.86B | |
+33.54% | 12.04B |